ReviewNature genetics2025
Expanding the scope of non-invasive prenatal screening.
Review in Nature genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cell-Based and Cell-Free Non-Invasive Prenatal Analysis of Preeclampsia: An Updated Review of Liquid Biopsy.Biomedicines · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-invasive prenatal screening has swiftly been implemented as a first- or second-tier test for common fetal aneuploidies and typically relies on sequencing maternal circulating cell-free DNA (cfDNA). This cfDNA comprises both the maternal and fetal genomes and the epigenetic features of its cells of origin. Here, we discuss how genetic findings beyond common fetal aneuploidies can provide important information about maternal and fetal health. Moreover, epigenetic and fragmentomic cfDNA features and cell-free RNA are emerging as powerful biomarkers of health and disease. We expound on the cfDNA and cell-free RNA analyses that have enabled first-trimester prediction of actionable pregnancy complications, such as preeclampsia, gestational diabetes, preterm birth, pregnancy-related immune-mediated disease activity and infections. This expanding scope of non-invasive prenatal screening promises to transform obstetric care from reactive to preventive, personalized medicine.
Indexed as
Identifiers
41102417What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.